In vitro electrophysiological investigations of the acute effects of linezolid and novel oxazolidinones on central nervous system neurons

Neuroscience

Volumn 180, Issue , 2011, Pages 53-63

  Kombian, S B ^a   Phillips, O A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antibacterial oxazolidinones; GABA; Glutamate; Linezolid; Neurotoxicity; Synaptic transmission

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ACETAMIDE; ADENOSINE A1 RECEPTOR ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR BLOCKING AGENT; LINEZOLID; MORPHOLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXAZOLIDINEDIONE DERIVATIVE; PH 027; PH 036; PH 084; PH 108; PIPERAZINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; HYPERPOLARIZATION; IN VITRO STUDY; INHIBITORY POSTSYNAPTIC POTENTIAL; MEMBRANE CONDUCTANCE; NERVE CELL; NERVE CELL EXCITABILITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; VOLTAGE CLAMP;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; HIPPOCAMPUS; NEURONS; NUCLEUS ACCUMBENS; OXAZOLIDINONES; PATCH-CLAMP TECHNIQUES; RATS; SYNAPTIC TRANSMISSION; TRIAZOLES;

EID: 79953167132     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.01.062     Document Type: Article

References (58)

1. Akins R.L., Haase K.K. Gram-positive resistance: pathogens, implications and treatment options. Pharmacol Ther 2005, 25(7):1001-1010.
2. Ananthalakshmi K.V.V., Edafiogho I.O., Kombian S.B. Concentration-dependent effects of anticonvulsant enaminone methyl 4-(4'-bromophenyl)aminocyclohex-3-en-6-methyl-2-oxo-1-oate on rat neuronal excitability in vitro. Neuroscience 2006, 141:345-356.
3. Apodaca A.A., Rakita R.M. Linezolid-induced lactic acidosis. N Engl J Med 2003, 348(1):86-87.
4. Barbachyn M.R., Ford C.W. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed 2003, 42:2010-2023.
5. Barrett J.F. Linezolid Pharmacia Corp. Curr Opin Investig Drugs 2000, 1(2):181-187.
6. Bozdogan B., Appelbaum P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004, 23(2):113-119.
7. Bressler A.M., Zimmer S.M., Gilmore J.L., Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004, 4(8):528-531.
8. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., Grega K.C., Hendges S.K., Toops D.S., Ford C.W., Zurenko G.E. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 1996, 39:673-679.
9. Cathala L., Guyon A., Eugene D., Paupardin-Tritsch D. Alpha2-adrenoceptor activation increases a cationic conductance and spontaneous GABAergic synaptic activity in dopaminergic neurones of the rat substantia nigra. Neuroscience 2002, 115:1059-1065.
10. Chao C.C., Sun H.Y., Chang Y.C., Hsieh S.T. Painful neuropathy with skin denervation after proloned use of linezolid. J Neurol Neurosurg Psychiatry 2008, 79(1):97-99.
11. Corallo C.E., Paull A.E. Linezolid-induced neuropathy. Med J Aust 2002, 177(6):332.
12. Di Paolo A., Malacarne P., Guidotti E., Danesi R., Del Tacca M. Pharmacological issues with linezolid: an updated critical review. Clin Pharmacokinet 2010, 49(7):439-447.
13. A inhibition of bed nucleus of the stria terminalis neurons projecting to the ventral tegmental area. J Neurosci 2004, 24:8198-8204.
14. Fauci A.S., Touchette N.A., Folkers G.K. Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis 2005, 11(4):519-525.
15. Ferry T., Ponceau B., Simon M., Issartel B., Petiot P., Boibieux A., Biron F., Chidiac C., Peyramond D. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005, 33:151-154.
16. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P. Infection due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357(9263):1179.
17. Han S.K., Chong W., Li L.H., Lee I.S., Murase K., Ryu P.D. Noradrenaline excites and inhibits GABAergic transmission in parvocellular neurons of rat hypothalamic paraventricular nucleus. J Neurophysiol 2002, 87:2287-2296.
18. Harvey J., Lacey M.G. Endogenous and exogenous dopamine depress EPSCs in rat nucleus accumbens in vitro via D1 receptors activation. J Physiol 1996, 492(Pt 1):143-154.
19. Hutchinson D.K. Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem 2003, 3:1021-1042.
20. Ippolito J.A., Kanyo Z.F., Wang D., Franceschi F.J., Moore P.B., Steitz T.A., Duffy E.M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 2008, 51:3353-3356.
21. Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 2006, 147(Suppl 1):S82-S88.
22. Johnson A.P., Tysall L., Stockdale M.W., Woodford N., Kaufmann M.E., Warner M., Livermore D.M., Asboth F., Allerberger F.J. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002, 21:751-754.
23. Kombian S.B., Ananthalakshmi K.V.V., Parvathy S.S., Matowe W.C. Substance P depresses excitatory synaptic transmission in the nucleus accumbens through dopaminergic and purinergic mechanisms. J Neurophysiol 2003, 89(2):728-737.
24. Kombian S.B., Ananthalakshmi K.V.V., Edafiogho I.O. Enaminones and norepinephrine employ convergent mechanisms to modulate excitatory synaptic transmission in rat nucleus accumbens in vitro. Eur J Neurosci 2006, 24:2781-2788.
25. Kombian S.B., Ananthalakshmi K.V.V., Edafiogho I.O. Norepinephrine and E139 interactions on epileptiform activity in the rat hippocampus in vitro. Med Princ Pract 2008, 17(5):365-372.
26. Lee E., Burger S., Shah J., Melton C., Mullen M., Warren F., Press R. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003, 37:1389-1391.
27. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
28. Lundstrom T.S., Sobel J.D. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid and daptomycin. Infect Dis Clin N Am 2004, 18:651-668.
29. Maletic V., Raison C.L. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009, 14:5291-5338.
30. McKinley S.H., Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroopthalmol 2005, 25(1):18-21.
31. Mody I., Leung P., Miller J.J. Role of norepinephrine in seizure-like activity of hippocampal pyramidal cells maintained in vitro: alteration by 6-hydroxydopamine lesions of norepinephrine-containing systems. Can J Physiol Pharmacol 1983, 61:841-846.
32. Morales-Molina J.A., Mateu-de Antonio J., Marín-Casino M., Grau S. Linezolid-associated serotonin syndrome: what can we learn from cases reported so far. J Antimicrob Chemother 2005, 56:1176-1178.
33. Nagel S., Kohrmann M., Huttner H.B., Storch-Hagenlocher B., Schwab S. Linezolid-induced posterior reversible leukoencephalopathy syndrome. Arch Neurol 2007, 64:746-748.
34. Narita M., Tsuji B.T., Yu V.L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis and serotonin syndrome. Pharmacotherapy 2007, 27(8):1189-1197.
35. Nau R., Sorgel F., Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010, 23(4):858-883.
36. Nicola S.M., Kombian S.B., Malenka R.C. Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors. J Neurosci 1996, 16:1591-1604.
37. Otis T.S., Staley K.J., Mody I. Perpetual inhibitory activity in mammalian brain slices generated by spontaneous GABA release. Brain Res 1991, 545(1-2):142-150.
38. Pennartz C.M., Groenewegen H.J., Lopes Da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 1994, 42:719-761.
39. Pennartz C.M., Kitai S.T. Hippocampal inputs to identified neurons in an in vitro slice preparation of the rat nucleus accumbens: evidence for feed-forward inhibition. J Neurosci 1991, 11(9):2838-2847.
40. Perry C.M., Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001, 61(4):525-551.
41. Pfizer Inc. (2006) Zyvoxam®2. Product Monograph, CPS, 2564-2568.
42. Phillips O.A., Udo E.E., Ali A.A.M., Al-Hassawi N. Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem 2003, 11(1):35-41.
43. Phillips O.A., Rotimi V.O., Jamal W.J., Shahin M., Verghese T.L. Comparative in vitro activity of PH-27, linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria. J Chemother 2003, 15(2):113-117.
44. Phillips O.A., Udo E.E., Ali A.A.M., Samuel S. Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones. Bioorg Med Chem 2005, 13(12):4113-4123.
45. Phillips O.A., Udo E.E., Abdel-Hamid M.E., Varghese R. Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole)methyl oxazolidinones. Eur J Med Chem 2009, 44:3217-3227.
46. Rahim S., Pillai K., Gold H.S., Venkataraman L., Ingelma K., Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003, 36:146-148.
47. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev Med Chem 2003, 3(2):129-136.
48. Reck F., Zhou F., Girardot M., Kern G., Eyermann C.J., Hales N.J., Ramsay R.R., Gravestock M.B. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005, 48:499-506.
49. Rucker J.C., Hamilton S.R., Bardenstein D., Isada C.M., Lee M.S. Linezolid-associated toxic optic neuropathy. Neurology 2006, 66(4):595-598.
50. Sinclair A., Arnold C., Woodford N. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance to enterococci. Antimicrob Agents Chemother 2003, 47(11):3620-3622.
51. Styers D., Sheehan D.J., Hogan P., Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006, 5:2.
52. Torres G.E., Amara S.G. Glutamate and monoamine transporters: new visions of form and function. Curr Opin Neurobiol 2007, 17(3):304-312.
53. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., Moellering R.B., Ferraro M.J. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
54. Villani P., Regazzi M.B., Viale P., Pagani L., Cristini F., Cadeo B., Carosi G., Bergoni R. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002, 46(3):936-937.
55. Wiselka M. Recently introduced antibiotics: a guide for the general physician. Clin Med 2004, 4(6):494-498.
56. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
57. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 1998, 5:137-162.
58. Zhou C.C., Swaney S.M., Shinabarger D.L., Stockman B.J. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother 2002, 46:625-629.